Vertex Reports Success In Second Major Hepatitis Drug Study

By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Vertex Pharmaceuticals Inc. (VRTX) reported the success of the second of three key late-stage studies of hepatitis-C treatment, telaprevir, essentially curing 72% of patients using the drug. ...
See all stories on this topic »

Health news @ read more

Random Health posts

Comments are closed.